TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: EMG activity per hour per night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Experiencing Clinical Worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of qualitative [18F]FSPG PET/CT interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Scale of Prodromal Symptoms Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in urinary biomarker value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: sensitivity MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: specificity MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: sensitivity transvaginal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: specificity transvaginal ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: sensitivity transvaginal ultrasound elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: specificity transvaginal ultrasound elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in allocation of care after intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum Severity of Each Adverse Event Per Patient
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of surgical resection necessity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reherniation Rates
Endpoint domain: Mortality/survival
Primary endpoint: Down syndrome detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Down syndrome false positive rate
Endpoint domain: Adverse events/effects
Primary endpoint: Down syndrome failure rate
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in diagnosis of LRTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first symptom relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increased sodium intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dynamic pain measured with coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve 0-4 Hours (AUC0-4h) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Response rate of CPI-0610
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of CPI-0610
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events associated with CPI-0610
Endpoint domain: Adverse events/effects
Primary endpoint: LUTS (Lower Urinary Tract Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary flow and postvoid residual volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Complete aneurysm occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in maximal isometric strength of the leg extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Contact point measurement between tibia and femur components
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AP (Atrial Pressure) in the aftermath of a stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Local Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in ADAS-cog13 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bubble Inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Disabilities of the Arm, Shoulder and Hand questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety and tolerability for ABI-007
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of the Mobile gamma camera for detection of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MDSC Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: MDSC Suppressive Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary aldosterone response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in left ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neuromelanin content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pupil Diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG Alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Micturition Frequency Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Nocturnal Micturition Frequency Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Urgency Episode Frequency (UEF) Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Antibiotics exposure at 28 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 Year Progression Free Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to phone an ambulance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of Cancer-related cognitive dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Therapeutic effects on Prostate Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Goal attainment scaling (GAS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Arm-hand ability (ARAT + WMFT tasks 1&2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse events Grade >/= 3
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cardiac events (CHF and cardiac death)
Endpoint domain: Adverse events/effects
Primary endpoint: Fatty acids quantification in erythrocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Early Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Molecular profile of cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Skindex-16 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Depression severity in dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in neutrophil surface marker expression profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in caregiving appraisal
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cytogenetic response (complete and partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute changes in ELISPOTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute changes in PRT (Panel Reactive T Cells)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute changes in lymphocyte subsets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time above 180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Safety Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of achievement of complete response or partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first use of analgesic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1 year Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Faces Pain Scale revised (FPS-r)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Free of MRI Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of gestational sacs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in EuroQol 5 dimension (EQ-5D) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Half-Life (T-HALF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood volume as measured by BVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total net fluid loss prior to hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients requiring diagnostic tests based on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of HER2 Negative, Positive, or Equivocal Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of the impalpable testis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of testicular vessels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of the vas deferens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Virtual ENGAGE-A Participants Who Attend Every Scheduled Therapy Session
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Average Satisfaction Score of Virtual ENGAGE-A Participants as Measured by the CSQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average Satisfaction Score of Community Clinicians (LCSW) as Measured by the TSQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax of CG5503 base
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of CG5503 base
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of CG5503 base
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in vitamin B12 concentration in infants' blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Quantitative Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder oversensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cortical excitability differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain structural differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain perfusional differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain connectivity differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emotional, attentional and behavior differences
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum postoperative pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of sultiame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Curve (AUC) of sultiame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic drug clearance of sultiame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution volume of sultiame
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MAARI Rate
Endpoint domain: Mortality/survival
Primary endpoint: Pathological diagnosis of liver perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Remission of Vasculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the Concentration-time Curve from Time 0 to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time until relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival (Phase II Futility Analysis)
Endpoint domain: Mortality/survival
Primary endpoint: Progression-free Survival (Final Results After Crossover)
Endpoint domain: Mortality/survival
Primary endpoint: New thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Temporal gait variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of Nevirapine resistance
Endpoint domain: Adverse events/effects
Primary endpoint: Olerud-Molander Ankle Score (OMAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Late-stage complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Six-Minute Walk Test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of successes in finger positions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Blood Count to monitor inflammation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum chemistry to monitor impact on serum chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-lead Electrocardiogram (ECG) to monitor cardiovascular health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time in glucose target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in peripheral vasculature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of interviews
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Effect of COVID-19 pandemic on academic performance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average studying time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evaluation of on-line education during lockdown
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Kinetics of neurotransmitters and hormones
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Constant score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Brachial Artery Flow-mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of DCC-dependent receptor labeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Characterization and quantification of biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in number and type of tumor infiltrating lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in expression level of Inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in tumor expression level of PD-L1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in HLA-type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Ce of propofol and remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Conversion to Probable Alzheimer's Disease
Endpoint domain: Mortality/survival
Primary endpoint: cerebral activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hematocrit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Creatinin rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: microcirculatory flow (cells / min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short term toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: post-transplant morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: post-transplant mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Shoulder Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in the Percentage of HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: annual relapse rate (ARR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Requiring Surgical Debridement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Auxological parameters (height, weight, Tanner stage, bone age)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective units of distress scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IgG trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentration-time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score of PANQUOL Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Death within 30 days of injury
Endpoint domain: Mortality/survival
Primary endpoint: Fluid administration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Prognostic Understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Allergen-specific Serum IgG4 and IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LA grade 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: clinical reasoning skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Asthma Control Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Safety of ESVV for CVI treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change of modified Rankin scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Peak plasma concentration of propionate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incremental area under the insulin profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With 7-Day Point Prevalence of Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in self-reported frequency of condom use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence Rate for the First Pneumonia Event
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of the First Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Event (All Types)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence Rate of Initiating Triple Combination Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year biochemical no evidence of disease rate
Endpoint domain: Mortality/survival
Primary endpoint: Emergency granulopoiesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation of LFI results with standard diagnostic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes